Privately owned and venture-backed, LeaderMed Group is built around a management team with deep experience advancing medicines in China and other international markets. Founded by CEO Joanne Jiang, Ph.D., the company helps pharmaceutical partners move promising treatments through clinical development and toward Asia-Pacific markets. Its team has led more than 60 innovative-drug trials and over 10 successful NDAs, experience that distinguishes LeaderMed’s cross-border approach.
APAC Pharmaceutical, LLCFounded by industry veterans with experience in China operations, APAC Pharmaceutical is a Maryland company known for connecting U.S.-managed chemistry projects with manufacturing in China. It develops and produces technically challenging raw materials for pharmaceutical and biotechnology companies, with work spanning early research through cGMP clinical manufacturing.COLUMBIA, MD
Clinigen GroupClinigen Group helps pharmaceutical and biotechnology companies move medicines through clinical development and into patients, combining clinical-trial supply management with managed access and global partnering. With regional teams across North America, Europe, Africa, Japan and Asia Pacific, the company has accelerated access to medicines in more than 130 countries. Clinigen also supplies hard-to-find and unlicensed medicines through its Clinigen Direct platform, drawing on more than 30 years of experience in that work.FARGO, ND
A&Z Pharmaceutical, IncFor more than 30 years, A&Z Pharmaceutical has built a global pharmaceutical business led by founder, CEO, and owner Emma Li Xu. Its 600-plus employees work from a 175,000-square-foot facility to help clients bring pharmaceutical and wellness products from concept to market, with the company’s FDA-registered, cGMP-certified site supporting that work.HAUPPAUGE, NY
Everest MedicinesEverest Medicines is a Shanghai-based, Hong Kong-listed biopharmaceutical company with an integrated presence spanning research through commercial production. Its work is aimed at bringing innovative treatments to patients in China and other global markets, with a particular emphasis on addressing serious unmet medical needs. The company’s Jiashan manufacturing site began operating in 2022 and includes a 58,000-square-meter facility built to Chinese, U.S. and EU GMP standards.New York, NY